Tornado Therapeutics
Biopharmaceutical company focused on discovery and development of next-generation small-molecule mTOR inhibitors (rapalog analogues) with improved selectivity profiles intended to treat aging-related conditions and other indications. Pipeline includes multiple in‑licensed small molecules progressing through lead optimization, IND‑enabling studies and preclinical efficacy testing. Organizational capabilities include medicinal chemistry, API/CMC development and partnerships/licensing.
Industries
N/A
Products
Small‑molecule mTOR inhibitor — IND‑enabling program (aging/immune/respiratory indications)
A program of orally bioavailable small‑molecule mTOR inhibitors progressing through IND‑enabling studies for indications including viral respiratory infections and oncology.
Small‑molecule mTOR inhibitor — preclinical candidate (oncology, autoimmune, dermatology)
Preclinical and lead‑stage small‑molecule candidates optimized for either TORC1 selectivity or combined TORC1/TORC2 potency across oncology, autoimmune and dermatology indications.
Small‑molecule mTOR inhibitor — IND‑enabling program (aging/immune/respiratory indications)
A program of orally bioavailable small‑molecule mTOR inhibitors progressing through IND‑enabling studies for indications including viral respiratory infections and oncology.
Small‑molecule mTOR inhibitor — preclinical candidate (oncology, autoimmune, dermatology)
Preclinical and lead‑stage small‑molecule candidates optimized for either TORC1 selectivity or combined TORC1/TORC2 potency across oncology, autoimmune and dermatology indications.
Services
Licensing and collaborative development
Negotiation and development of in‑licensing agreements and collaborative R&D arrangements to advance compound portfolios.
Licensing and collaborative development
Negotiation and development of in‑licensing agreements and collaborative R&D arrangements to advance compound portfolios.
Expertise Areas
- Medicinal chemistry and small‑molecule discovery
- mTOR biology and translational geroscience
- API/CMC development and scale‑up
- Preclinical candidate selection and IND‑enabling studies
Key Technologies
- Small‑molecule kinase inhibitors
- TORC1/TORC2 selectivity profiling
- Preclinical aging and immune function models
- IND‑enabling study design